Meet with... DARPA's Biological Technologies Office
Meet with... DARPA's Biological Technologies Office
FHI 360 CONFERENCE CENTER , 1825 Connecticut Avenue NW , Washington , DC 20009
June 02, 2015 from 12:30 PM to 14:30 PM (EST)
$10 - $35
The Defense Advanced Research Projects Agency (DARPA) recently launched an important initiative for national security, incorporating biology, engineering, and computer science in a single focus. Since 1958, DARPA has been leading efforts to prevent strategic surprise from negatively impacting U.S. national security and creating strategic surprise for U.S. adversaries. As the Department of Defense's (DoD) primary innovation engine, DARPA undertakes projects that are finite in duration, but that create lasting change. DARPA has funded some of the most cutting-edge and highly classified scientific research in the U.S. Their biomedical projects often include efforts to treat battlefield injuries and to boost the physiological capacities of soldiers. The Biological Technologies Office (BTO) has over 20 different active programs to cultivate fundamental research, discoveries, and applications. BTO focus areas include:
- Restoring and maintaining warfighter abilities
- Harnessing biological systems
- Applying biological complexity
DARPA is looking to engage with a wide spectrum of potential collaborators. Leaders from the life science industry, including entrepreneurs, partners and investors, are encouraged to apply today to meet with a representative from DARPA's BTO!
10:30am | Registration and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
12:30 | One-on-one Meetings*
*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period ends May 7th. APPLY HERE
About DARPA's Biological Technologies Office (BTO):
The mission of the Biological Technologies Office (BTO) is to foster, demonstrate, and transition breakthrough fundamental research, discoveries, and applications that integrate biology, engineering, and computer science for national security. BTO seeks to establish and invest in new communities of scientific interest at the intersection of traditional and emerging disciplines. Its investment portfolio goes far beyond life sciences applications in medicine to include areas of research such as human-machine interfaces, microbes as production platforms, and deep exploration of the impact of evolving ecologies and environments on U.S. readiness and capabilities. BTO's programs operate across a wide range of scales, from individual cells to complex biological systems including mammalian and non-mammalian organisms and the macro- and micro-environments in which they operate.
DARPA participating Representative:
Geoffrey Ling | Director, Biological Technologies Office at DARPA
Dr. Geoffrey Ling is the founding Director of the Biological Technologies Office at DARPA. Dr. Ling began his DARPA service in 2004 as a Program Manager in the Defense Sciences Office (DSO). He created and managed a broad research portfolio, encompassing over $400M in funding and spanning neuroscience, infectious disease, pharmacology, and battlefield medicine. His most prominent programs included the Revolutionizing Prosthesis (RP) and Preventing Violent Explosive Neuro Trauma (PREVENT). RP is an effort to develop a brain controlled robot prosthetic arm for amputees, and it has been featured twice on CBS's "60 Minutes." PREVENT aims to develop new understanding and treatment of blast-induced TBI and has been profiled in major news outlets, including USA Today and the NY Post.
Dr. Ling also serves as an attending neuro critical care physician at Johns Hopkins Hospital. He retired from the US Army in 2012 after serving as a military intensive care physician with multiple deployments to Iraq and Afghanistan. As a military intensive care physician, he deployed with the 44th Medical Command (Airborne) to Afghanistan in 2003 and Baghdad, Iraq in 2005. One of his units in Iraq, the 10th Combat Support Hospital, awarded him the first "Physician of the Month" distinction. In addition, he went on all four Gray Team missions to both Iraq and Afghanistan (2009-2012). The Gray Team was composed of senior military medical officers selected by ADM Mullen, then Chairman of the Joint Chiefs of Staff, to evaluate and recommend improvements to war-theater TBI care.
From 2012-2013, Dr. Ling served as the Assistant Director for Medical Innovation in the Science Division at the White House Office of Science and Technology Policy. He received his Ph.D. in pharmacology from Cornell University, and M.D. from Georgetown University. Dr. Ling is board certified in both Neurology and Neuro Critical Care.
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until June 1st (or full).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on May 7th. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved. All companies accepted for a one-on-one meeting will be notified of acceptance and scheduled meeting time via email on May 20th.
FHI 360 CONFERENCE CENTER
1825 Connecticut Avenue NW
Washington, DC 20009
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Thomas McNerney & Partners, NCATS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.